Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis

Cancer Treatment Reviews

Volumn 40, Issue 9, 2014, Pages 1048-1055

  Templeton, Arnoud J ^a   Diez Gonzalez, Laura ^b   Ace, Olga ^a   Vera Badillo, Francisco ^a   Šeruga, Boštjan ^c   Jordán, Joaquín ^b   Amir, Eitan ^a   Pandiella, Atanasio ^d   Ocaña, Alberto ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

^d UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Breast cancer; Meta analysis; Overexpression; Prognosis; Receptor tyrosine kinase; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN TYROSINE KINASE; EGFR PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; FGFR3 PROTEIN, HUMAN;

BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; DATA ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ASSAY; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVIEW; SENSITIVITY ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; BREAST TUMOR; ENZYMOLOGY; FEMALE; METABOLISM; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; RISK;

BREAST NEOPLASMS; FEMALE; HUMANS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3;

EID: 84928757277     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.08.003     Document Type: Review

References (54)

1. Ocana A., Amir E., Seruga B., et al. The evolving landscape of protein kinases in breast cancer: clinical implications. Cancer Treat Rev 2013, 39:68-76.
2. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 03:211-225.
3. Hynes N.E., Stern D.F. The biology of erbB-2/neu/HER2 and its role in cancer. Biochim Biophys Acta 1994, 1198:165-184.
4. Cruz J.J., Ocana A., Del Barco E., et al. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 2007, 18:421-430.
5. Alonso A., Sasin J., Bottini N., et al. Protein tyrosine phosphatases in the human genome. Cell 2004, 117:699-711.
6. Sun T., Aceto N., Meerbrey K.L., et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 2011, 144:703-718.
7. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
8. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
9. Ocana A., Pandiella A., Siu L.L., et al. Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol 2010, 7(8):200-209.
10. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676-3685.
11. Ravdin P.M., Chamness G.C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene 1995, 159:19-27.
12. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
13. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
14. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
15. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
16. Rimawi M.F., Shetty P.B., Weiss H.L., et al. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 2010, 116:1234-1242.
17. Turner N., Pearson A., Sharpe R., et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010, 70:2085-2094.
18. Stommel J.M., Kimmelman A.C., Ying H., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318:287-290.
19. Esparis-Ogando A., Ocana A., Rodriguez-Barrueco R., et al. Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Ann Oncol 2008, 19:1860-1869.
20. Hilberg F., Roth G.J., Krssak M., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008, 68:4774-4782.
21. Kutluk Cenik B., Ostapoff K.T., Gerber D.E., et al. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther 2013, 12:992-1001.
22. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62:4645-4655.
23. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6:e1000100.
24. Deeks J., Higgins J.P.T., Altaman D.G. Analysing data and undertaking meta-analyses 2011, The Cochrane Collaboration, [Chapter 9].
25. Ryden L., Jirstrom K., Haglund M., et al. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat 2010, 120:491-498.
26. Taunk N.K., Goyal S., Moran M.S., et al. Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy. Radiother Oncol 2010, 96:204-208.
27. Abd El-Rehim D.M., Pinder S.E., Paish C.E., et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004, 91:1532-1542.
28. Sun S., Jiang Y., Zhang G., et al. Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol 2012, 105:773-779.
29. Chiu C.G., Masoudi H., Leung S., et al. HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Ann Surg 2010, 251:1107-1116.
30. Kim J.H., Cho Y.H., Park Y.L., et al. Prognostic significance of insulin growth factor-I receptor and insulin growth factor binding protein-3 expression in primary breast cancer. Oncol Rep 2010, 23:989-995.
31. Viale G., Rotmensz N., Maisonneuve P., et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009, 116:317-328.
32. Liu D., He J., Yuan Z., et al. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 2012, 29:401-405.
33. Manning G., Whyte D.B., Martinez R., et al. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
34. Olayioye M.A., Neve R.M., Lane H.A., et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19:3159-3167.
35. Peto R., Davies C., Godwin J., et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379:432-444.
36. Vera-Badillo F.E., Templeton A.J., de Gouveia P., et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2014, 1:106. djt319.
37. Ocana A., Vera-Badillo F., Seruga B., et al. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst 2013, 105:266-273.
38. Spears M., Taylor K.J., Munro A.F., et al. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat 2012, 132:463-470.
39. Montero J.C., Esparis-Ogando A., Re-Louhau M.F., et al. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene 2014, 9(33):148-156.
40. Baselga J., Gomez P., Greil R., et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013, 31:2586-2592.
41. Ocana A., Amir E., Vera F., et al. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011, 29:254-256.
42. Plaza-Menacho I., Morandi A., Robertson D., et al. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 2010, 29:4648-4657.
43. Casanovas O., Hicklin D.J., Bergers G., et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
44. Angevin E., Lopez-Martin J.A., Lin C.C., et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 2013, 19:1257-1268.
45. Okamoto I., Kaneda H., Satoh T., et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010, 9:2825-2833.
46. Castellvi J., Garcia A., Rojo F., et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006, 107:1801-1811.
47. Kallel I., Khabir A., Boujelbene N., et al. EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia. J Recept Signal Transduct Res 2012, 32:142-149.
48. Magkou C., Nakopoulou L., Zoubouli C., et al. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res 2008, 10:R49.
49. Kuroso K., Imai Y., Kobayashi M., et al. Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis. Pathobiology 2010, 77:231-240.
50. Tsutsui S., Ohno S., Murakami S., et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002, 71:67-75.
51. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
52. Sassen A., Rochon J., Wild P., et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008, 10:R2.
53. Wiseman S.M., Makretsov N., Nielsen T.O., et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 2005, 103:1770-1777.
54. Witton C.J., Reeves J.R., Going J.J., et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200:290-297.